AIDS Treatment Update, Issue 55, July 1997
Keith Alcorn

All participants in ProCom will receive treatment with four drugs for the first four months - two nucleoside analogue reverse transcriptase inhibitors (ddI plus d4T) plus two protease inhibitors (nelfinavir plus new formulation saquinavir). Treatment will then continue with either all four drugs or with only two drugs (either ddI plus d4T, or nelfinavir plus saquinavir) for another 16 months. If treatment is considered to be failing, either in terms of the viral load, CD4 count or clinical disease, participants may receive the four drugs on an open basis.

People with a CD4 count below 350 or a viral load measurement above 20,000 will be eligible if they are starting HIV treatment for the first time or have had prior treatment (but none for a month before joining the trial) with AZT, 3TC, ddC or loviride.

970701
ATU05504

Copyright © 1997 - AIDS Treatment Update. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. NAM Publications 16a Clapham Common Southside, London, England SW4 7AB; TEL: 01-71-627-3200 (from outside the UK: +44-171-627-3200); FAX: 01-71-627-3101 (from outside the UK: +44=171-627-3101)  info@nam.org.uk  http://www.nam.org.uk